Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Earns Overweight Rating from Analysts at Stephens

Stephens began coverage on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM - Free Report) in a report released on Tuesday, Marketbeat reports. The firm issued an overweight rating and a $25.00 price target on the biotechnology company's stock.

A number of other research analysts also recently weighed in on ATNM. Cantor Fitzgerald reiterated an overweight rating and set a $21.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. Maxim Group upped their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a buy rating in a research note on Tuesday, March 19th. HC Wainwright reissued a buy rating and issued a $50.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, April 29th. Finally, StockNews.com upgraded Actinium Pharmaceuticals from a sell rating to a hold rating in a report on Sunday, May 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of $25.60.

Actinium Pharmaceuticals Price Performance

Actinium Pharmaceuticals stock traded up $1.03 during midday trading on Tuesday, reaching $9.89. The stock had a trading volume of 951,882 shares, compared to its average volume of 327,647. Actinium Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $10.24. The firm has a market capitalization of $294.52 million, a price-to-earnings ratio of -5.78 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM - Get Free Report) last announced its quarterly earnings data on Friday, April 26th. The biotechnology company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.11. On average, sell-side analysts expect that Actinium Pharmaceuticals will post -1.48 EPS for the current year.

Institutional Trading of Actinium Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Brandywine Global Investment Management LLC purchased a new position in Actinium Pharmaceuticals in the third quarter valued at $1,033,000. Vanguard Group Inc. lifted its position in Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company's stock valued at $11,325,000 after purchasing an additional 82,113 shares during the period. Sanders Morris Harris LLC acquired a new position in Actinium Pharmaceuticals during the 1st quarter worth approximately $78,000. Finally, Creative Financial Designs Inc. ADV raised its stake in shares of Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company's stock worth $101,000 after buying an additional 3,175 shares in the last quarter. Hedge funds and other institutional investors own 27.50% of the company's stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.